사이토키네틱스(CYTK)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $68.78 (-1.63%), 시가총액 $7.87B, 52주 최저~최고 $29.84 ~ $70.10.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and
사이토키네틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
사이토키네틱스의 현재 주가는 $68.78 (-1.63%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
사이토키네틱스의 시가총액은 약 $7.87B입니다.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating